Czech National Bank’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.11M Buy
13,710
+307
+2% +$54.7K 0.02% 473
2026
Q1
$2.31M Buy
13,403
+426
+3% +$79K 0.02% 480
2025
Q4
$2.59M Buy
12,977
+477
+4% +$86.5K 0.02% 476
2025
Q3
$1.96M Buy
12,500
+498
+4% +$79.1K 0.01% 490
2025
Q2
$1.82M Buy
12,002
+257
+2% +$34.3K 0.01% 488
2025
Q1
$1.77M Buy
11,745
+657
+6% +$110K 0.02% 489
2024
Q4
$2.05M Buy
11,088
+571
+5% +$110K 0.02% 470
2024
Q3
$2.07M Buy
10,517
+701
+7% +$146K 0.02% 466
2024
Q2
$2.03M Buy
9,816
+791
+9% +$179K 0.02% 455
2024
Q1
$2.45M Buy
9,025
+41
+0.5% +$9.79K 0.03% 427
2023
Q4
$2.12M Buy
8,984
+23
+0.3% +$4.52K 0.03% 437
2023
Q3
$1.76M Buy
8,961
+2,902
+48% +$596K 0.03% 446
2023
Q2
$1.27M Buy
6,059
+65
+1% +$12.9K 0.03% 447
2023
Q1
$1.21M Buy
5,994
+39
+0.7% +$8.84K 0.03% 451
2022
Q4
$1.3M Buy
5,955
+44
+0.7% +$9.61K 0.03% 432
2022
Q3
$1.16M Buy
+5,911
New +$1.28M 0.03% 435

Other funds holding CRL